Cullinan Therapeutics, Inc.
0 products tracked · names used in filings: Cullinan Therapeutics, Inc.
Upcoming milestones
Sat 27 Feb 2027🇺🇸 PDUFA datecompany-announcedin 105 days
Zipalertinib: PDUFA target action date (EGFR exon 20 insertion NSCLC previously treated with platinum-based chemotherapy (accelerated approval, monotherapy))
Cullinan Therapeutics, Inc. (CGEM); zipalertinib; NDA; status: set; "An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027."; filed 2026-10-02 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.